CLINICAL_TRIALS
trial_result
· 2019-10-15
Clinical Trial Update: A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) [Phase 2]
Summary
Phase 2 trial evaluating IW-3718 in patients with symptomatic gastroesophageal reflux disease has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ironwood Pharmaceuticals, Inc. | Conditions: Gastroesophageal Reflux Disease | Phase 2 | Status: COMPLETED | Results posted: 2019-10-15